Drug Approval | August 30, 2024
Natco Pharma announces submission of TABRECTA to USFDA
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
Trazodone tablets are indicated for the treatment of major depressive disorder in adults
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
The product combines proven efficacy of Doxylamine succinate 20 mg and Pyridoxine hydrochloride 20 mg in an Extended Release formulation
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
This approval has come from the company's finished dosage form manufacturing facility
Subscribe To Our Newsletter & Stay Updated
